News and Trends 20 Sep 2022 Fooditive creating bee-free honey using precision fermentation biotech Dutch plant-based ingredients company Fooditive is scaling up existing products and introducing the latest developments: LowSalt & Bee-free-Honey. “We feel like the next chapter of this journey has just begun. With the support from our shareholders, clients, partners and our team we are focused to increase our impact and make a fundamental change in the […] September 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Dyania Health raises $5.3M to help speed up clinical trials Dyania Health was founded in 2019 to address a significant and unsolved problem for clinical trials. That is, the process of manual chart review to pre-screening patients for clinical research is cumbersome and time-consuming. The process to match patients on very specific and time-sensitive clinical trial criteria typically takes 18 to 24 months for most […] September 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Kamari Pharma raises $8M in investment for development of drugs for skin diseases An $8 million investment has been raised by Kamari Pharma following investment from the Guangzhou-Israel Biotechnology Fund (GIBF) that creates added value for Israeli, European and American companies looking to expand in China. Kamari Pharma was established at the end of 2018 by the leading Israeli based biotechnology funds Pontifax and Arkin Bioholdings. Prior to […] September 19, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, Israel, is to lead CanceRNA, a global consortium aiming to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses. While RNA-based therapies, namely mRNA vaccines, shone during the pandemic and saved millions of lives, they have yet to be successfully tested […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Tokyo scientists reveal possible new direction for getting rid of cancer cells Scientists from Tokyo University of Science have revealed how autophagy regulates the elimination of transformed cells that can initiate cancer. The elimination is necessary to maintain tissue integrity. The scientists have found that intact autograph vacuoles are indispensable in mediating competitive elimination of the cancer cells. They also noted perturbation of autophagy prevents cell […] September 19, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Taiwan-based Anyong Biotechnology first to employ seafood stem-cell freezing Anyong Biotechnology is the first company in its region to use the most advanced freezing technology in Asia, it was announced today (September 19). The aquatic food processing company based in Taiwan has employed Cells Alive System (CAS) technology from Japan. Originally a medical-grade technology for freezing stem cells, Anyong says CAS is highly praised […] September 19, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 GENFIT to acquire Versantis to expand liver disease portfolio GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. GENFIT said the acquisition fits its strategic vision of becoming a global leader in ACLF (acute-on-chronic […] September 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Biologics manufacturing facility launched by Evotec SE in Toulouse Construction of a biologics manufacturing facility commenced on Friday (September 16). It is being built by Evotec at its Campus Curie in Toulouse, is the second facility of its kind, and the first in Europe. It will use Just – Evotec Biologics’ flexible J.POD technology to deliver clinical and commercial manufacturing capacity for biologics. Therapeutic […] September 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Cyxone receives approval for phase 2b rheumatoid arthritis study Swedish biotech company Cyxone has received approval from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA approves Heron Therapeutics’ post-op nausea and vomiting drug Heron Therapeutics, Inc. says the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults. Heron Therapeutics’ APONVIE is the first and only IV formulation of aprepitant for PONV prevention. Administered via a single 30-second IV injection, APONVIE reaches […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 CellResearch Corporation announces positive results of phase I diabetic foot ulcer study CellResearch Corporation, a Singapore-based biopharma company says it has successfully closed the first phase I study for CorLiCyte, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy. CorLiCyte is in development for the treatment of serious […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA boosts Antengene pancreatic cancer treatment Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The company said the ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email